Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

$Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer$

Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer

A surgical technique appears to offer quick and effective relief for debilitating spinal fractures often suffered by patients with metastatic cancer, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan.

11 Oct 2010

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010

$Balloon kyphoplasty offers effective relief for debilitating spinal fractures suffered by metastatic cancer patients$

Balloon kyphoplasty offers effective relief for debilitating spinal fractures suffered by metastatic cancer patients

11 Oct 2010

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's lorvotuzumab mertansine (IMGN901) targeted anticancer compound at the 35th European Society for Medical Oncology (ESMO) Conference being held in Milan, Italy, October 8-12, 2010.

11 Oct 2010

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

Onyx Pharmaceuticals, Inc. today announced that it will delay its New Drug Application (NDA) filing for carfilzomib based on a recent meeting with the Chemistry, Manufacturing and Controls (CMC) review division of the U.S. Food and Drug Administration (FDA).

7 Oct 2010

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

7 Oct 2010

Aeterna Zentaris' AEZS-130 demonstrates potential as oral diagnostic test for AGHD

Aeterna Zentaris Inc., today announced that an interim review of a Phase 3 trial of AEZS-130 (macimorelin, SolorelTM), demonstrates the compound may provide a simple, well-tolerated and safe oral diagnostic test for Adult Growth Hormone Deficiency (AGHD). The data was presented earlier today by Beverly M.K. Biller, M.D. of the Harvard Medical School/Massachusetts General Hospital in Boston, at the 5th International Congress of the Growth Hormone Research Society (GRS) and the Insulin-like Growth Factors (IGF) Society in New York City.

6 Oct 2010

Amgen to present oncology portfolio results at ESMO Congress

Amgen today announced that results from several important studies from the Company's ncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.

6 Oct 2010

Otsuka opens Canadian operations

Otsuka Canada Pharmaceutical Inc. has opened its first Canadian office, in the Montreal suburb of Saint-Laurent. This marks a major milestone in the continued growth of Otsuka in North America.

4 Oct 2010

Study shows hypomethylation increases through progression of multiple myeloma

DNA methylation, a modification of DNA linked to gene regulation — is altered with increasing severity in a blood cancer called multiple myeloma, according to a study by Mayo Clinic and the Translational Genomics Research Institute (TGen).

4 Oct 2010

Report finds development of multiple myeloma is tied to 'hypomethylation'

DNA methylation - a modification of DNA linked to gene regulation - is altered with increasing severity in a blood cancer called multiple myeloma, according to a study by Mayo Clinic and the Translational Genomics Research Institute (TGen).

1 Oct 2010

Keryx commences Zerenex Phase 3 study for hyperphosphatemia in patients with ESRD on dialysis

Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

29 Sep 2010

Senesco fiscal 2010 revenue decreases to $140,000

Senesco Technologies, Inc. reported financial results for the 12 months ended June 30, 2010 ("Fiscal 2010").

29 Sep 2010

Cylene commences CX-4945 Phase I trial in multiple myeloma

Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd.

24 Sep 2010

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Signal Genetics, a privately held predictive genetic testing company focused on oncology, today announced the company will work with Array BioPharma to help push forward both companies' goals of markers for patient selection, helping bring personalized medicine and companion diagnostics to patients with multiple myeloma, a cancer of the bone marrow and antibody producing cells.

23 Sep 2010

Masonic Cancer Center receives five-year program project research grants from NCI

Two of the University of Minnesota Masonic Cancer Center's leading physician-scientists on research and treatment of cancers of the blood and bone marrow Philip McGlave, M.D., and Jeffrey Miller, M.D., have received renewed five-year program project research grants totaling almost $26 million from the National Cancer Institute (NCI).

23 Sep 2010

Chronix Biomedical completes Series E financing

Chronix Biomedical today announced that it has completed a Series E financing that raised $1.8 million from existing and new investors. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix's serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.

20 Sep 2010

Arno Therapeutics closes private placement to advance cancer treatment

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced that it has closed a private placement of its securities resulting in gross proceeds to the company of over $15 million.

14 Sep 2010

Researchers find risk prediction model for VTE in cancer patients

For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology.

10 Sep 2010

IMF and CHPF join to promote awareness of myeloma in China

The International Myeloma Foundation (IMF), the oldest and largest foundation dedicated to improving the life and care of myeloma patients, today announced plans to sign a cooperative agreement with the Chinese Health Promotion Foundation (CHPF), an agency that operates under the Chinese Ministry of Health, to promote awareness of myeloma in China and to encourage measures to prevent and combat the disease.

9 Sep 2010